Information Provided By: 
Fly News Breaks for June 26, 2017
SGEN
Jun 26, 2017 | 09:46 EDT
Piper Jaffray analyst Edward Tenthoff noted that Seattle Genetics' Phase 3 ECHELON-1 data showed only a "modest" benefit but he still thinks the data is "good enough" to warrant approval for ADCETRIS in a frontline indication, likely next year. Tenthoff, who forecasts ADCETRIS sales of about $295M this year and $375M in 2018, keeps a Neutral rating and $48 price target on Seattle Genetics shares.
News For SGEN From the Last 2 Days
There are no results for your query SGEN
